« Prix Hermès de l'innovation » for Novartis Access
Novartis Access is the 2016 winner of the "Prix Hermès de l'innovation" in the category “Improvement of the human condition”. Jürgen Brokatzky-Geiger, Global Head Corporate Responsibility, collected the award during the official ceremony in Paris on June 14.
The "Prix Hermès de l'innovation" recognizes companies or organizations which have excelled in integrating the best state of knowledge into products and services offering more satisfaction to individuals and society. It is owned by the European Institute for Creative Strategies and Innovation.
Videos from the award ceremony:
Novartis Access includes 15 generic and patented medicines to address cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer. The portfolio is offered to governments, NGOs and other public-sector healthcare providers in low and lower middle income countries for USD 1 per treatment, per month. The medicines in the portfolio have been selected based on their medical relevance: they are either on or pertain to a class included in the WHO Model List of Essential Medicines, or belong to the most frequently prescribed medicines in these disease areas. Novartis Access launched in Kenya in 2015 and we strive to reach 30 countries over the coming years depending on government and stakeholder demand.
Novartis Access is the latest addition to our company’s efforts to enhance access to healthcare for patients at every level of income. www.novartisaccess.com
